ClinicalTrials.gg
Not yet recruitingNCT06500091Updated Jul 15, 2024

TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

A Phase 2 interventional study of TQB2916 injection + doxorubicin hydrochloride for injection and TQB2916 injection+penpulimab injection in Soft Tissue Sarcoma and Melanoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Not yet recruiting at 11 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing doxorubicin in Sarcoma — 13 open to participants now, 14 under way, 2 of them phase 3. Doxorubicin · Sarcoma.

Planned enrollment
23rd of 60
54 · median 42
Started
2024
the only one that year
Phase 2
31 of 65
7 open now
Primary completion
2026-06
later than 3 of 13 live
Registered
61st of 65
by date

Among the 65 studies testing doxorubicin in Sarcoma, this one is the 23rd largest by planned enrollment of the 60 interventional ones that give a count, is the only one that started in 2024, is one of 31 in phase 2, reaches primary completion later than 3 of the 13 other live ones, and was the 61st registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

13 of the 65 studies testing doxorubicin in Sarcoma are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing doxorubicin in Sarcoma, or all of them as a file.
02

Study summary

This project is a clinical trial on the efficacy and safety of TQB2916 injection combined with chemotherapy or penpulimab injection in solid tumors. This project is divided into two cohorts. Cohort 1 aims to explore the safety and efficacy of specific subtypes of soft tissue sarcoma in subjects; Cohort 2 aims to explore safety and efficacy in subjects with undifferentiated pleomorphic sarcoma and melanoma. A total of 54 subjects are planned to be enrolled in this project.

03

Conditions studied

  • Soft Tissue Sarcoma
  • Melanoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects voluntarily joined this study, signed an form, and had good compliance.
  2. Age: 18-75 years old; Performance Status (ECOG PS) score: 0-1 points; The expected survival period exceeds 3 months.
  3. Patients with locally advanced or unresponsive / soft tissue sarcoma and melanoma diagnosed by pathology and unable or refused surgery. Cohort 1contains the following subtypes: "dedifferentiated liposarcoma, highly differentiated liposarcoma with dedifferentiated components, leiomyosarcoma (excluding uterine leiomyosarcoma)", and cohort 2 contains undifferentiated pleomorphic sarcoma and melanoma.
  4. Cohort 1: No previous history of failure of anthracycline-based chemotherapy. Cohort 2: Previously treated with standard of care.
  5. Cohort 2: Previously treated.
  6. According to 1.1 standard, it is confirmed that there is at least one .
  7. The main organs are functioning well.
  8. Female participants of childbearing age should agree to use measures during the study period and within 6 months after the end of the study; Within 7 days prior to enrollment, the serum pregnancy test was negative and must be a non lactating subject; Male participants should agree to use contraceptive measures during the study period and within 6 months after the end of the study period.

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diseases and medical history:

    1. Has experienced or currently suffers from other malignant tumors within 5 years.
    2. Unresolved toxic reactions above CommonTerminology Criteria for Adverse Events level 1 caused by any previous treatment;
    3. The research treatment began with significant surgical treatment, open , or obvious traumatic injury;
    4. Long term unhealed wounds or fractures;
    5. Arterial/venous thrombotic events that have occurred within 6 months and affect current normal function;
    6. Individuals with a history of psychiatric drug abuse who are unable to quit or have mental disorders;
    7. Individuals who have previously undergone splenectomy or received splenic radiotherapy within 3 months prior to enrollment;
    8. Currently present with congenital hemorrhagic or coagulation diseases, or currently undergoing treatment with warfarin;
    9. Subjects with any severe and/or uncontrolled diseases, including:

      • Blood pressure control is still not ideal after dual drug treatment;
      • Suffering from ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia; ≥ Grade 2 unstable angina pectoris;
      • Active or uncontrolled severe infection or unexplained fever>38.5 °C;
      • Cirrhosis and active hepatitis *;
      • Active syphilis patients;
      • Renal failure requiring hemodialysis or peritoneal dialysis;
      • Have a history of immunodeficiency;
      • Poor control of diabetes;
      • Urinary routine indicates urine protein ≥++;
      • Individuals with epilepsy who require treatment;
      • Weight\<40 kg and \<18.5 kg/m2, or weight loss of ≥ 10% within 3 months.
  2. Tumor related symptoms and treatment:

    1. Has received surgery, chemotherapy, radiation therapy, or other anti-cancer therapies before the start of the research treatment;
    2. Before the start of the study treatment, he received the treatment of traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National MedicalProducts Administration (NMPA) approved drug directions;
    3. Cohort 1: Previously used doxorubicin exceeding 200mg/m2;
    4. Cohort 2: Undifferentiated multidirectional sarcoma that has previously received more than 2 types of anti vascular tyrosine kinase inhibitors (TKIs), or has previously received relevant immunotherapy drugs;
    5. Previously received antibodies or fusion proteins targeting 0;
    6. Imaging shows that the tumor invades large blood vessels or has unclear boundaries with large blood vessels, or the researcher determines that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
    7. Uncontrollable pleural effusion, pericardial effusion, or ascites that still require repeated drainage;
    8. Severe bone damage caused by tumor bone may occur in the presence or after enrollment;
    9. Uncontrollable pain related to tumor bone metastasis;
    10. There was central nervous system metastasis before enrollment.
  3. Research and treatment related:

    1. History of administration before the start of research treatment or planned live attenuated vaccine administration during the study period;
    2. There is a clear bleeding tendency or bleeding symptoms before the first use of medication;
    3. Individuals who have experienced severe reactions after using monoclonal antibodies, or who are allergic to known components of the drug;
    4. Active diseases that require systemic treatment have occurred within 2 years prior to the start of the research treatment.
    5. Diagnosed with immunodeficiency or undergoing systemic therapy or any other form of therapy.
  4. Participated in clinical trials of other anti-tumor drugs within the first 4 weeks of grouping.
  5. According to the researcher's judgment, there are individuals with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or individuals who are deemed unsuitable for enrollment due to other reasons.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    TQB2916 injection + doxorubicin hydrochloride for injection

    TQB2916 injection + doxorubicin hydrochloride for injection, 21 days as a treatment cycle.

    Drug: TQB2916 injection + doxorubicin hydrochloride for injection

  • Experimental
    TQB2916 injection+penpulimab injection

    TQB2916 injection+penpulimab injection , 21 days as a treatment cycle.

    Drug: TQB2916 injection+penpulimab injection

Interventions

  • DrugTQB2916 injection + doxorubicin hydrochloride for injection

    Drug pages: TQB2916 · Doxorubicin

    TQB2916 is a humanized immune gamma globulins 2 (IgG2) monoclonal antibody targeting CD40. The mechanism of action of doxorubicin is mainly to destroy the DNA structure of tumor cells, thereby killing malignant tumors. It interferes with the DNA synthesis process of cancer cells by targeting DNA and inhibiting enzymes in DNA replication and repair. In addition, doxorubicin can also trigger cross-link breaks in DNA, leading to apoptosis of cancer cells.

  • DrugTQB2916 injection+penpulimab injection

    Drug pages: TQB2916 · Penpulimab

    TQB2916 is a humanized IgG2 monoclonal antibody targeting CD40. Penpulimab injection is a programmed cell death protein 1 (PD-1) immune checkpoint inhibitor.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Objective response rate refers to the percentage of complete response (CR) or partial response (PR) subjects determined by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or modified RECIST 1.1 for immune based therapeutics(guidelines for response criteria for use in trials testing Immunotherapeutics(iRECIST)) (CR and PR) under iRECIST criteria can occur after imaging disease progression).

    Time frame: Up to 48 weeks

  2. Progression-Free Survival (PFS)

    PFS will be defined as median number of months from the date of randomization until the first documented sign of disease progression or death due to any causes, whichever occurs first.

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Overall survival (OS)

    Overall survival defined as the time from enrollment to death from any cause.

    Time frame: Up to 2 years

  2. Duration of Response (DOR)

    DOR will be defined as median number of months from date of first documented objective response until first documented sign of disease progression or death due to any causes.

    Time frame: Up to 48 weeks

07

Study locations

11 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2024; primary completion for Jun 2026, 23 months later.

Of 227 phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 92. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 15, 2024
StartEst.
Jul 2024
Primary completionEst.
Jun 2026
CompletionEst.
Dec 2026
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06500091
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Jul 2024 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 15, 2024

Study contacts

Jilong Yang, Doctor
Contact
yangjilong@tjmuch.com
18622221626
Yong Chen, Doctor
Contact
chenyong@shca.org.cn
18017317571

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: TQB2916 · Doxorubicin · Penpulimab

Start the discussion